Rhabdomyosarcoma (RMS) is a devastating pediatric sarcoma. The survival outcomes remain poor for patients with relapsed or metastatic disease. Effective targeted therapy is lacking due to our limited knowledge of the underlying cellular and molecular mechanisms leading to disease progression. In this study, we used functional assays in vitro and in vivo (zebrafish and xenograft mouse models) to demonstrate the crucial role of HDAC6, a cytoplasmic histone deacetylase, in driving RMS tumor growth, self-renewal and migration/invasion. Treatment with the HDAC6-selective inhibitor, Tubastatin A, recapitulates the HDAC6 loss-of-function phenotypes. HDAC6 regulates cytoskeletal dynamics to promote tumor cell migration and invasion. RAC1, a Rho family GTPase, is an essential mediator of HDAC6 function, and is necessary and sufficient for RMS cell migration and invasion. High expression of RAC1 correlates with poor clinical prognosis in RMS patients. Targeting the HDAC6-RAC1 axis represents a promising therapeutic option for improving survival outcomes of RMS patients. Rhabdomyosarcoma (RMS) is a devastating pediatric sarcoma that displays morphological and molecular evidence for incomplete myogenic differentiation. RMS is roughly divided into two major subtypes by histologic features, embryonal (ERMS) and alveolar (ARMS). Genetically, ERMS is characterized by mutations in the receptor tyrosine kinase/RAS/PIK3CA axis found in at least 90% of cases 1 , and most ARMS cases harbor the PAX3 (or PAX7)-FOXO1 fusion transcript 2 . Despite the genetic differences, the prognosis for relapsed or metastatic disease remains poor regardless of the subtype. Effective targeted therapy is lacking due to our poor understanding of events leading to relapse or metastasis of RMS.
INTRODUCTION
In this study, we investigate the function of HDAC6 in various RMS features utilizing both in vitro and in vivo functional assays and demonstrate that HDAC6 is essential for RMS cell growth, migration/invasion and self-renewal. RAC1, a Rho GTPase, is a key player in mediating HDAC6 function in regulating RMS cell migration/invasion. High expression of RAC1 correlates with poor clinical survival of RMS patients. Overall, targeting the HDAC6-RAC1 axis may have significant therapeutic benefits for RMS patients.
RESULTS

Expression of HDAC6 in RMS
We first assessed expression of HDAC6 in primary human RMS samples by immunohistochemistry. HDAC6 expression was detected primarily in the cytoplasm at variable intensity levels in most cases of ARMS (11 of 11) and ERMS (6 of 7) ( Fig. 1 A-F) . In contrast, five cases of pediatric muscle did not express HDAC6. A panel of ERMS (RD and SMS-CTR) and ARMS cell lines (Rh5 and Rh30) also showed cytoplasmic and perinuclear expression of HDAC6 by immunofluorescence ( Fig. 1 G-J) . Overall, our findings showed that HDAC6 is differentially expressed in RMS cells compared to normal muscle, and that HDAC6 functions predominantly in the cytoplasm of RMS cells.
Conserved role of HDAC6 in promoting tumor growth in RMS
To assess HDAC6 loss-of-function effects tumor cell growth, we generated CRISPR/Cas9-mediated HDAC6 gene knockout in a panel of RMS cell lines (ERMS: RD, 381T, SMS-CTR; ARMS: Rh5 and Rh30). Targeted disruption of HDAC6 resulted in a significant reduction of tumor cell growth (Fig. 1 K) . To assess the specificity of HDAC6 knockout on tumor cell growth, we performed rescue experiments by overexpressing Green Fluorescent Protein (GFP) as a control, wild-type HDAC6 (modified to be Cas9-resistant) and catalyticallydead (cd) HDAC6 in RD cells harboring tamoxifen-inducible CRISPR/Cas9 targeting HDAC6.
Overexpression of Cas9-resistant wild-type HDAC6 alleviated the HDAC6 knockout-induced growth phenotype in comparison with overexpression of cd HDAC6 or GFP, indicating that the effect of HDAC6 knockout on tumor cell growth is specific and that the catalytic activity of HDAC6 is required for its function in regulating RMS tumor cell growth (Fig. 1 L) . Depletion of HDAC6 protein from CRISPR/Cas9-mediated gene knockout and overexpression of wild-type and cd HDAC6 were confirmed by Western blots (Fig. 1 M) .
To assess the effects of HDAC6 loss-of-function on tumor growth in vivo, we generated CRISPR/Cas9-mediated hdac6 knockout in a conserved zebrafish model of KRAS(G12D)induced ERMS 28 ( Fig. 1 N) . Zebrafish ERMS tumors harboring hdac6 knockout showed significantly reduced tumor growth by at least 50% compared to tumors harboring the GFPscrambled gRNAs as a control ( Fig. 1 O-S, p < 0.01), indicating that hdac6 has a conserved role in promoting ERMS tumor growth.
HDAC6 promotes RMS tumor growth by modulating cell cycle progression and tumor cell differentiation
To determine the tumor cell phenotypes that contributed to reduced tumor cell growth following targeted disruption of HDAC6, we assessed for alterations in cell cycle progression, cell death and cell differentiation in RMS cells with HDAC6 knockout. RD and Rh5 cells with HDAC6 knockout showed arrest in G1 or G2/M phases of cell cycle ( Fig. 2 A) but no significant change in programmed cell death ( Fig. 2 B) . RMS cells are pathologically characterized by an arrest in myogenic differentiation 16, 18 . We showed that targeted disruption of HDAC6 significantly increased myogenic differentiation (approximately 2-3 folds; p < 0.01) compared to controls, based on immunofluorescence staining for myosin heavy chain ( Fig. 2 C-G). RMS cells harboring targeted HDAC6 also showed increased expression of genes (e.g. MYOD1, MYH8, CKM) involved in myogenesis following targeted disruption of HDAC6 (results for RD shown in 
HDAC6 promotes RMS tumor cell migration and self-renewal
The effects of HDAC6 loss-of-function on the migratory behavior and self-renewal capacity of RMS cells were also assessed. Targeted disruption of HDAC6 by CRISPR/Cas9 in RD and Rh5 cells resulted in reduced migration by scratch wound healing ( Fig. 3 A-B ) and transwell assays ( Fig. 3 C-D). Using the sphere assay as a surrogate in vitro assay for assessing tumor cell stemness and self-renewal 29 , we showed that RD and Rh5 cells with HDAC6 knockout exhibited reduced frequency and size of sphere formation ( Fig. 3 E-F). Expression levels of stem cell markers such as SOX2 and NANOG were also reduced in RD cells with HDAC6 knockout ( Fig. 3 G) . Overall, our findings using in vitro functional assays suggest that HDAC6 plays an important role in regulating migratory and self-renewal capacity of RMS tumor cells.
Treatment with Tubastatin A recapitulates the HDAC6 loss-of-function effects in RMS
To assess whether treatment of RMS cells with Tubastatin A, a selective HDAC6 inhibitor, could recapitulate the loss-of-function effects of HDAC6 on RMS cells, we first showed that treating a panel of RMS cell lines (RD, SMS-CTR, Rh5 and Rh30) with Tubastatin A in vitro significantly inhibited tumor cell growth in a dose-dependent manner ( Fig. 4 A-B; Fig.   S1 A-B). In scratch wound healing and self-renewal assays, RD and Rh5 cells treated with Tubastatin A (200 nM) showed reduced migration and self-renewal capacity, respectively ( Fig. 4 C-F).
To assess the effect of Tubastatin A treatment in RMS tumor growth in vivo, RMS xenografts generated from RD and Rh5 cells were treated with Tubastatin A by intraperitoneal injections at 10 mg per kg per mouse every 3 days for 21 days. RD and Rh5 xenografts treated with Tubastain A showed at least 50% reduction in tumor growth compared to those treated with DMSO as a vehicle control ( Fig To assess whether Tubastatin A treatment affects the self-renewal capacity of RMS cells in vivo, we treated zebrafish ERMS tumors with Tubastatin A (10 µM) and DMSO (vehicle) for 7 days and performed limiting dilution transplantation assays. Tumor engraftment was monitored weekly until day 28 post-transplantation. In 3 independent experiments, Tubastatin A-treated ERMS tumors transplanted at limiting dilutions (10 4 , 10 3 and 10 2 cells) showed approximately 6-9 fold decrease in self-renewal frequency by Extreme Limiting Dilution (ELDA) analysis 30 (Table 1) . Overall, treatment of RMS cells with Tubastatin A mimics the loss-of-function effects of HDAC6 on tumor cell growth, migration and self-renewal capacity and represents a promising agent for targeted therapy for RMS.
HDAC6 alters the cytoskeletal dynamics to affect RMS cell migration via RAC1
HDAC6 has previously been shown to acetylate the elements of cytoskeleton such as tubulin and actin 20,31 . To assess whether HDAC6 plays a role in modulating the dynamics of cytoskeleton to promote migration of RMS tumor cells, we first showed that there were increased levels of acetylated tubulin in RD and Rh5 RMS cells following targeted disruption of HDAC6 by CRISPR/Cas9 or treatment with Tubastatin A ( Fig. 5 A; Fig. S2 A) . Overexpressing either wild-type but not catalytically-dead (cd) Cas9-resistant HDAC6 in RD cells harboring targeted disruption of HDAC6 alleviated the migratory defect in comparison to overexpression GFP as a control ( Fig. 5 B) , indicating that the deacetylase activity is required for the HDAC6 function in regulating RMS cell migration. To assess the effects of HDAC6 loss-of-function on actin-dependent cytoskeletal dynamics, we showed by phalloidin staining that there was loss of membrane ruffles, folds and filopodia as well as altered organization of cytoplasmic actin filament in RD and Rh5 cells harboring Cas9-mediated targeted disruption of HDAC6 following Epidermal Growth Factor (EGF) stimulation in the setting of serum starvation ( RAC1 is a small GTPase of the Rho family which has been shown to mediate a variety of cellular events including cell adhesion, motility and polarity 32,33 . However, the causal relationship between HDAC6 and RAC1 in mediating the cytoskeletal dynamics to promote cancer cell migration is unclear. To assess whether RAC1 contributes to HDAC6-mediated changes in the cytoskeleton dynamics and cell motility of RMS cells, we first showed that RAC1 and HDAC6 co-localized at the regions of cell membrane ruffles and folds ( Fig. 5 D) , and that RAC1-GTP levels were reduced in RMS cells with HDAC6 knockout ( Overexpressing the constitutively activated mutant form of RAC1 (RAC1V12) alleviated the migration phenotype ( Fig. 5 F) but did not alter the growth phenotype of RD cells with HDAC6 knockout ( Fig. 5 G) . A dominant-negative form of RAC1 (RAC1N17) and a constitutively active form of mutant RhoA (RhoAV14), another Rho family GTPase, did not rescue the migration defect in RMS cells with HDAC6 knockout (Fig. 5 F) . Using a RAC1-GTP pull-down assay, RAC1V12 immunoprecipitated increased level of RAC1-GTP compared to GFP control and RAC1N17, supporting the constitutive activity of RAC1V12 ( Fig. 5 H) . Taken together, HDAC6 alters the microtubule and actin-dependent cytoskeletal dynamics to promote RMS cell migration via RAC1, and there is no cross talk between close members of Rho GTPases in this context.
RAC1 is essential for RMS cell migration and invasion
As RAC1 is a key mediator of HDAC6 function in regulating RMS cell migration, we next assessed whether RAC1 is essential for RMS cell migration through loss-of-function and gain-of-function studies. Cultured RD and Rh5 RMS cells with targeted disruption of RAC1 showed reduced migratory capacity by the scratch wound healing assay (p < 0.0001; Figure 6 A-B; Figure S3 A). Similarly, RD and Rh5 cells treated with the selective RAC1 inhibitor, EHop-016, also showed reduced migration (Figure S3 B) .
To assess the gain-of-function effects of RAC1 on RMS cell migration and invasion in vivo, KRASG12D-driven zebrafish ERMS tumors co-expressing RAC1V12 or an empty vector as control were transplanted into syngeneic CG1 zebrafish at 10,000 cell per fish via dorsal subcutaneous route, and the fish with engrafted tumors were imaged weekly for tumor cell migration. We showed that by 21 days, zebrafish ERMS tumor cells co-expressing RAC1V12 demonstrate more aggressive growth and increased migration along the dorsal-ventral body axis compared to the control empty vector co-expressing tumor cells ( 
RAC1 is associated with poor prognosis in RMS
To assess whether HDAC6 or RAC1 expression is associated with clinical prognosis in RMS, we correlated expression levels of HDAC6 or RAC1 mRNA expression in 81 cases with survival data (63 fusion-negative and 18 fusion-positive). Kaplan-Meier curves were generated based on gene expression values dichotomized into over-and under-expressed groups using the median expression value within each cohort as a cutoff. While high expression of HDAC6 did not correlate with overall survival, high expression of RAC1 correlated with decreased overall survival ( Figure 6 F; log rank test, p = 0.02842, HR = 2.36, 95% CI = 1.095 -5.084). The findings suggest that expression of RAC1 can be potentially used as a clinical prognostic indicator in RMS patients.
DISCUSSION
In this study, we have demonstrated through in vitro and in vivo functional assays that HDAC6 regulates RMS tumor growth by modulating cell cycle progression and differentiation.
HDAC6 also plays an important role in regulating the self-renewal capacity and migration/invasion of RMS cells. RAC1 is an important mediator of HDAC6 function in RMS cell migration/invasion, and high expression of RAC1 correlates with poor clinical prognosis in RMS patients.
HDAC6 has been shown to deacetylate tubulin, a subunit of microtubule, and cortactin, an actin-associated protein, to affect cytoskeletal dynamics 20,31 . A study in mouse embryonic fibroblasts demonstrates that functional HDAC6 is required for RAC1 activation 23 . However, the functional relationship among HDAC6, the microtubule and the actin filament in driving cancer cell invasion/migration is unclear. In our study, we showed that HDAC6 deacetylase the tubulin subunits of microtubule, and its deacetylase activity is required to promote RMS cell migration.
HDAC6 also plays a crucial role in regulating the actin-dependent cytoskeletal dynamics required for RMS cell migration. This is supported by our findings that HDAC6 and RAC1 colocalized in the areas of membrane ruffles and filopodia, which are the changes in the actin elements required for cell motility and invasion, and RMS cells with targeted disruption of HDAC6 showed reduced formation of membrane ruffling and filopodia. In addition, RAC1 has been shown previously to be required for actin polymerization, stress fiber formation and focal adhesion complex assembly 32 . In this study, loss of HDAC6 resulted in reduced RAC1 GTPase activity, and activated mutant form of RAC1 (RAC1V12) alleviated the migration defect of RMS cells with HDAC6 knockout. Overall, our findings indicate the deacetylate activity of HDAC6 and activation of RAC1 are essential for the HDAC6-mediated effects on actin-dependent cytoskeletal dynamics required for RMS cell migration and invasion. The crosstalk between the microtubules and actin elements in regulating cellular processes such as cell migration is beginning to be recognized 34 . HDAC6 likely coordinates the direct or indirect interaction between the microtubules and the actin or its associated molecules to promote RMS cell migration and invasion. Further investigation is required to assess whether acetylation of tubulin or other substrates by HDAC6 directly affects RAC1 activation and in turn actin dynamics or HDAC6 independently alters the microtubule and actin dynamics to regulate RMS cell motility. RAC1 is required for actin cytoskeletal reorganization, a process required for cell migration/invasion during cancer metastasis. Increased expression or activity of RAC1 is associated with metastatic potential in multiple cancer types (e.g. breast, liver and upper urinary tract) [35] [36] [37] . However, the functional requirement for RAC1 in cancer cell migration and invasion has not been clearly demonstrated. In this study, we used loss-of-function and gain-of-function studies in vitro and in vivo to demonstrate that RAC1 is necessary and sufficient for active migration/invasion of RMS cells. High expression of RAC1 also correlates with poor clinical outcomes in RMS patients. Our findings indicate that RAC1 can serve not only as a therapeutic target for reducing invasive and metastatic potential of RMS cells, but also a potential clinical prognostic indicator for predicting RMS patient outcomes.
The self-renewal capacity of tumor initiating cells contributes to cancer relapse and therapy resistance 12 . So far there are limited studies on characterizing the role of HDAC6 in regulating cancer stemness and self-renewal capacity. In glioblastoma, HDAC6 is required for maintaining the glioma stem cell stemness and contributes through its interaction with the Sonic Hedgehog (SHH) signaling pathway to the promote the radio-resistant phenotype 26 . Through in vitro sphere assays and in vivo limiting dilution assays, we showed that targeted disruption of HDAC6 by the CRISPR technology and treatment with Tubastatin A, a selective HDAC6 inhibitor, resulted in reduced cancer stemness and self-renewal capacity of RMS cells. RMS spheres generated in vitro have been shown to be enriched for a stem cell marker, CD133, and are resistant to treatment with standard-of-care chemotherapy agents 14 . While further investigation is required to determine the pathways modulated by HDAC6 to regulate selfrenewal of RMS cells, our findings suggest that targeted therapy using HDAC6 selective inhibitors against cancer stemness represents a promising option for preventing relapse and treatment resistance in RMS.
Our knowledge in the molecular mechanisms underlying RMS self-renewal and metastasis is limited. Using in vitro and in vivo functional assays, we have characterized the unique role of HDAC6 in regulating RMS tumor growth, self-renewal and migration/invasion. As RAC1 serves as an essential downstream mediator of HDAC6 function in RMS cell migration and invasion, targeting the HDAC6-RAC1 axis will likely improve survival outcomes of RMS patients. 
METHODS
CRISPR/Cas9 Gene Targeting in human RMS
